Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.
Sharp uptake in use of new weight loss and glucose-lowering medications
- Post author:admin
- Post published:April 16, 2025
- Post category:uncategorized
- Post comments:0 Comments